Advance Nanotechnology-Based Drug Delivery Systems for Alzheimer's Disease: Advancements and Future Perspectives.

Current Alzheimer research Pub Date : 2025-06-05 DOI:10.2174/0115672050380959250530112247

Kuldeep Singh, Jeetendra Kumar Gupta, Gaurav Lakhchora, Divya Jain, Alok Bhatt, Mukesh Chandra Sharma, Mvnl Chaitanya, Mohammad Tabish

{"title":"Advance Nanotechnology-Based Drug Delivery Systems for Alzheimer's Disease: Advancements and Future Perspectives.","authors":"Kuldeep Singh, Jeetendra Kumar Gupta, Gaurav Lakhchora, Divya Jain, Alok Bhatt, Mukesh Chandra Sharma, Mvnl Chaitanya, Mohammad Tabish","doi":"10.2174/0115672050380959250530112247","DOIUrl":null,"url":null,"abstract":"<p><p>Alzheimer's Disease (AD) is a progressive neurodegenerative disorder characterized by cognitive decline and memory loss, significantly impacting the quality of life for affected individuals. This manuscript explores various innovative therapeutic strategies aimed at enhancing drug delivery to the brain, particularly through the use of nanotechnology. This paper discussed the application of Solid Lipid Nanoparticles (SLNs), dendrimers, and Polymeric Nanoparticles (PNPs) in targeting the Central Nervous System (CNS) to improve bioavailability and therapeutic efficacy. The findings indicate that these advanced delivery systems can enhance brain penetration, reduce Amyloid-Beta (Aβ) deposition, and improve cognitive functions in animal models of AD. Furthermore, the review highlights the challenges associated with these technologies, including limited scalability and potential toxicity, while suggesting future directions for research and development in the field of AD treatment.</p>","PeriodicalId":94309,"journal":{"name":"Current Alzheimer research","volume":" ","pages":""},"PeriodicalIF":0.0000,"publicationDate":"2025-06-05","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":"0","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"Current Alzheimer research","FirstCategoryId":"1085","ListUrlMain":"https://doi.org/10.2174/0115672050380959250530112247","RegionNum":0,"RegionCategory":null,"ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"","JCRName":"","Score":null,"Total":0}

引用次数: 0

Abstract

Alzheimer's Disease (AD) is a progressive neurodegenerative disorder characterized by cognitive decline and memory loss, significantly impacting the quality of life for affected individuals. This manuscript explores various innovative therapeutic strategies aimed at enhancing drug delivery to the brain, particularly through the use of nanotechnology. This paper discussed the application of Solid Lipid Nanoparticles (SLNs), dendrimers, and Polymeric Nanoparticles (PNPs) in targeting the Central Nervous System (CNS) to improve bioavailability and therapeutic efficacy. The findings indicate that these advanced delivery systems can enhance brain penetration, reduce Amyloid-Beta (Aβ) deposition, and improve cognitive functions in animal models of AD. Furthermore, the review highlights the challenges associated with these technologies, including limited scalability and potential toxicity, while suggesting future directions for research and development in the field of AD treatment.

查看原文本刊更多论文

基于纳米技术的阿尔茨海默病药物递送系统：进展和未来展望。

阿尔茨海默病（AD）是一种以认知能力下降和记忆丧失为特征的进行性神经退行性疾病，严重影响患者的生活质量。这篇论文探讨了各种创新的治疗策略，旨在加强药物输送到大脑，特别是通过使用纳米技术。本文讨论了固体脂质纳米颗粒（SLNs）、树状大分子和聚合物纳米颗粒（PNPs）在靶向中枢神经系统（CNS）方面的应用，以提高生物利用度和治疗效果。研究结果表明，这些先进的递送系统可以增强AD动物模型的大脑渗透，减少淀粉样蛋白- β (Aβ)沉积，并改善认知功能。此外，该综述强调了与这些技术相关的挑战，包括有限的可扩展性和潜在的毒性，同时提出了AD治疗领域未来的研究和开发方向。

本文章由计算机程序翻译，如有差异，请以英文原文为准。

求助全文

约1分钟内获得全文求助全文

来源期刊

Current Alzheimer research

自引率

0.00%

发文量